Literature DB >> 3035014

Lysosomal enzyme release from human monocytes by particulate activators is mediated by beta-glucan inhibitable receptors.

M J Janusz, K F Austen, J K Czop.   

Abstract

Human peripheral blood monocytes ingest particulate activators and generate leukotrienes via a trypsin-sensitive, beta-glucan-inhibitable receptor. The incubation of monolayers of monocytes with from 4 X 10(5) to 2 X 10(8) zymosan or glucan particles resulted in a dose-dependent release of up to 9% +/- 1.9 and 17.8% +/- 5.3 (mean +/- SD, n = 3) of the lysosomal enzyme, N-acetylglucosaminidase, into the culture medium. Lysosomal enzyme release occurred throughout the 2-hr period studied, with the greatest rate of N-acetyl-glucosaminidase release occurring during the first hour; the presence of 5 micrograms/ml of cytochalasin B accelerated this process when zymosan was the agonist. The preincubation of monocytes with from 0.5 to 500 micrograms/ml of soluble yeast beta-glucan inhibited N-acetylglucosaminidase release by 4 X 10(7) zymosan and glucan particles in a dose-dependent manner, with 50% inhibition occurring with 50 micrograms/ml of soluble yeast beta-glucan (mean +/- SD, n = 3). Preincubation with as much as 5 mg/ml of yeast mannan had no inhibitory effect on N-acetylglucosaminidase release. The pretreatment for 30 min of monolayers of monocytes with 50 micrograms/ml of affinity-purified trypsin, which selectively inactivates the monocyte-phagocytic response to particulate activators, also fully inhibited lysosomal enzyme release induced by zymosan and glucan particles. The inhibitory effects of a soluble ligand, yeast beta-glucan, and of trypsin pretreatment on lysosomal enzyme release correspond to the inhibitory effect of these agents on monocyte phagocytosis of zymosan and glucan particles and thus indicates ligand specificity for the beta-glucan receptor in the release of stored intracellular mediators.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3035014

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Release of gelatinase and superoxide from human mononuclear phagocytes in response to particulate Tamm Horsfall protein.

Authors:  D B Thomas; M Davies; J D Williams
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

2.  Fungal beta-glucan interacts with vitronectin and stimulates tumor necrosis factor alpha release from macrophages.

Authors:  E J Olson; J E Standing; N Griego-Harper; O A Hoffman; A H Limper
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

Review 3.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

4.  Anti-infective effect of poly-beta 1-6-glucotriosyl-beta 1-3-glucopyranose glucan in vivo.

Authors:  A B Onderdonk; R L Cisneros; P Hinkson; G Ostroff
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

5.  Human polymorphonuclear leucocytes stimulated by tumour necrosis factor-alpha show increased adherence to extracellular matrix proteins which is mediated via the CD11b/18 complex.

Authors:  H L Thompson; K Matsushima
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

6.  Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans.

Authors:  S M Levitz; D J DiBenedetto
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

7.  Effects of adhesins from mannose-resistant Escherichia coli on mediator release from human lymphocytes, monocytes, and basophils and from polymorphonuclear granulocytes.

Authors:  Y Ventur; J Scheffer; J Hacker; W Goebel; W König
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Enhancement of human monocyte beta-glucan receptors by glucocorticoids.

Authors:  J Kay; J K Czop
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.